Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Somanta Pharmaceuticals
Irvine, California, United Statessomanta.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Somanta's lead asset, sodium phenylbutyrate, was in Phase 2 trials for CNS and blood cancers, with orphan designations like glioblastoma multiforme. Preclinical assets targeting drug-resistant tumors and tumor vasculature showed proof-of-concept but limited published clinical data. Platform-enabled targeted activation of drugs in hypoxic tumor microenvironments. Somanta was acquired before any assets reached market approval.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small moleculeMonoclonal antibodyProdrug
- Industry
- Biotech
02
Partnerships
Virium Pharmaceuticals (for sodium phenylbutyrate)
Beyond the preview
Go deeper on Somanta Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Somanta Pharmaceuticals.